ClinicalTrials.gg
TerminatedNCT03043651Updated Oct 22, 2020Results posted

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

A Phase 3 interventional study of Oral treprostinil in Pulmonary Hypertension Associated With HFpEF, sponsored by United Therapeutics. Terminated at 82 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-10-22.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated by Sponsor

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.

Enrollment
13th of 37
48 · median 32
Started
2018
with 2 others
Phase 3
15 of 38
1 open now
Registered
27th of 38
by date
Lead sponsor
25 of 38
United Therapeutics

Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 13th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2018, is one of 15 in phase 3, and was the 27th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing treprostinil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

This was an open-label study to evaluate the safety of continued therapy with oral treprostinil in subjects who completed Study TDE-HF-301. This study provided long-term, open-label data regarding the effect of continued long-term oral treprostinil therapy for the treatment of pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Subject visits occurred at Baseline, Weeks 6, 12, 18, 24, and every 12 weeks thereafter until either oral treprostinil was commercially available to treat PH associated with HFpEF or the study was discontinued by the Sponsor.

The Sponsor terminated Studies TDE-HF-301 and TDE-HF-302 on 14 October 2019 due to slow enrollment. Safety data from the final subject in Study TDE-HF-302 were recorded on 02 March 2020. Due to the lower than expected number of subjects enrolled, the planned secondary efficacy-related endpoints were not analyzed.

Read the detailed description

Study TDE-HF-302 was a multicenter, open-label study in subjects participating and completing all required visits for Study TDE-HF-301. This study assessed the long-term safety of oral treprostinil in subjects with PH associated with HFpEF.

Subjects received oral treprostinil as 0.125-, 0.25-, 1-, and 2.5-mg sustained-release tablets. For subjects who were randomly allocated to receive oral treprostinil in Study TDE-HF-301, the initial dose of oral treprostinil was the same as the final dose in Study TDE-HF-301. Subjects randomly allocated to receive placebo in Study TDE-HF-301 were administered the initial dose of oral treprostinil at 0.125 mg 3 times daily (TID). Dose increases could occur in 0.125-mg increments every 72 hours at the discretion of the Investigator up to 6 mg TID, the maximum allowable dose determined by the Data Monitoring Committee during Study TDE-HF-301. Doses of study drug were to be increased in the absence of dose-limiting drug-related adverse events (AEs) to ensure that each subject received the optimal dose throughout the study. Subjects returned for visits at Weeks 6, 12, 18, and 24, and every 12 weeks thereafter. Subjects who terminated the study early were asked to return to the study center for a final evaluation.

Safety assessments consisted of AEs, clinical laboratory parameters, and clinical assessment of heart failure signs and symptoms.

Due to the lower than expected number of subjects enrolled, the planned secondary efficacy-related endpoints were not analyzed.

03

Conditions studied

  • Pulmonary Hypertension Associated With HFpEF

Keywords

  • Pulmonary Hypertension
  • HFpEF
  • 6-Minute Walk Test
  • Oral Treprostinil
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject participated in Study TDE-HF-301, remained on study drug, was compliant with study procedures and assessments during Study TDE-HF-301, and completed through Week 24 of that study.

Exclusion criteria

Exclusion Criteria:

  1. The subject was pregnant or lactating.
  2. The subject was prematurely discontinued from Study TDE-HF-301 for any reason.
  3. The subject developed a concurrent illness or condition during Study TDE-HF-301, which, in the opinion of the Investigator, represented a risk to the subject's overall health if they enrolled in this study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Oral treprostinil

    Sustained-release tablets for TID administration

    Drug: Oral treprostinil

Interventions

  • Sustained-release oral tablets for TID administration

    Also known as: Treprostinil diethanolamine, Treprostinil diolamine

06

What researchers measure

Primary outcomes

  1. Long-term Safety of Oral Treprostinil in Subjects With PH Associated With HFpEF for Subjects Who Completed Study TDE-HF-301

    The primary objective of this study was to evaluate the long-term safety of oral treprostinil in subjects with PH associated with HFpEF for subjects who completed Study TDE-HF-301. The number of subjects with adverse events during the study is reported as the primary outcome measure, which was the only outcome measurement reported for this Sponsor-terminated study.

    Time frame: Baseline through study completion, up to approximately 25 months

07

Results

Posted Oct 22, 2020

Participant flow

Participant flow — Overall Study
MilestoneOral Treprostinil
Started48
Completed0
Not completed48
Withdrew: Death1
Withdrew: Progressive disease2
Withdrew: Adverse event2
Withdrew: Withdrawal by subject4
Withdrew: Study terminated by sponsor39

Outcome measures

PrimaryLong-term Safety of Oral Treprostinil in Subjects With PH Associated With HFpEF for Subjects Who Completed Study TDE-HF-301

The primary objective of this study was to evaluate the long-term safety of oral treprostinil in subjects with PH associated with HFpEF for subjects who completed Study TDE-HF-301. The number of subjects with adverse events during the study is reported as the primary outcome measure, which was the only outcome measurement reported for this Sponsor-terminated study.

Time frame:
Baseline through study completion, up to approximately 25 months
Reported as:
Count of participants · Participants
Long-term Safety of Oral Treprostinil in Subjects With PH Associated With HFpEF for Subjects Who Completed Study TDE-HF-301
ParticipantsOral Treprostinil
Long-term Safety of Oral Treprostinil in Subjects With PH Associated With HFpEF for Subjects Who Completed Study TDE-HF-30147

Adverse events

Collected over The study duration was 25 months overall. The study was discontinued by the Sponsor on 14 October 2019 due to slow enrollment in the parent study, TDE-HF-301.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Treprostinil1/48 (2.1%)19/48 (39.6%)47/48 (97.9%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventOral Treprostinil
Acute kidney injuryRenal and urinary disorders4/48
Cardiac failureCardiac disorders3/48
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/48
Cardiac failure acuteCardiac disorders2/48
Cardiac failure congestiveCardiac disorders2/48
HypokalaemiaMetabolism and nutrition disorders2/48
Pleural effusionRespiratory, thoracic and mediastinal disorders2/48
PneumoniaInfections and infestations2/48
Atrial fibrillationCardiac disorders1/48
AzotaemiaRenal and urinary disorders1/48
Most frequent other events
Showing 10 of 44
Most frequent other events
EventOral Treprostinil
HeadacheNervous system disorders31/48
DiarrhoeaGastrointestinal disorders26/48
NauseaGastrointestinal disorders17/48
FatigueGeneral disorders15/48
Pain in extremityMusculoskeletal and connective tissue disorders13/48
DizzinessNervous system disorders9/48
DyspnoeaRespiratory, thoracic and mediastinal disorders9/48
Oedema peripheralGeneral disorders9/48
Back painMusculoskeletal and connective tissue disorders8/48
CoughRespiratory, thoracic and mediastinal disorders8/48

Baseline characteristics

All Subjects

Age, Continuous
Age, Continuous(years)Oral Treprostinil
Median76.0 (46 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Oral Treprostinil
Female35
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oral Treprostinil
Hispanic or Latino1
Not Hispanic or Latino47
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oral Treprostinil
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White43
More than one race0
Unknown or Not Reported0
08

Study locations

82 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Banner University Medical Center Phoenix
    Phoenix, Arizona 85006, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • VA Healthcare System of Greater Los Angeles
    Los Angeles, California 90073, United States
  • University of California Los Angeles Pulmonary Division
    Los Angeles, California 90095, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90211, United States
  • University of California - Davis Medical Center
    Sacramento, California 95817, United States
  • Santa Barbara Cottage Hospital
    Santa Barbara, California 93105, United States
  • Aurora Denver Cardiology Associates
    Aurora, Colorado 80012, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • South Denver Cardiology
    Littleton, Colorado 80120, United States
  • MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Medical Faculty Associates, George Washington University
    Washington, District of Columbia 20037, United States
  • Bay Area Cardiology Associates
    Brandon, Florida 33511, United States
  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
  • St. Vincent's Lung, Sleep, and Critical Care Specialists
    Jacksonville, Florida 33204, United States
  • Central Florida Pulmonary Group, P.A.
    Orlando, Florida 32803, United States
  • Florida Hospital
    Orlando, Florida 32806, United States
  • University of South Florida ; Tampa General Hospital
    Tampa, Florida 33606, United States
  • Cleveland Clinic of Florida
    Weston, Florida 33331, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Piedmont Physicians Georgia Lung
    Austell, Georgia 30309, United States
  • WellStar Medical Group
    Marietta, Georgia 30060, United States
  • University of Illinois at Chicago Hospital
    Chicago, Illinois 60612, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Advocate Christ Medical Center
    Oak Lawn, Illinois 60453, United States
  • OSF HealthCare
    Peoria, Illinois 61614, United States
  • Indiana University Health Methodist Research Institute, INC
    Indianapolis, Indiana 46202, United States
  • Community Heart and Vascular Hospital
    Indianapolis, Indiana 46250, United States
  • Saint Vincent Hospital and Health Services
    Indianapolis, Indiana 46260, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 55242, United States
  • Iowa Heart Center
    West Des Moines, Iowa 50266, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • Kentuckiana Pulmonary Associates
    Louisville, Kentucky 40202, United States
  • University of Louisville Physicians Outpatient Center
    Louisville, Kentucky 40202, United States
  • Chest Medicine Associates
    South Portland, Maine 04106, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • St. Elizabeth's Medical Center
    Brighton, Massachusetts 02135, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Spectrum Health Medical Group
    Grand Rapids, Michigan 49503, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • St. Luke's Hospital
    Chesterfield, Missouri 63017, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Barnabas Health Lung Center
    Newark, New Jersey 07112, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Pulmonary Health Physicians, PC
    Syracuse, New York 13066, United States
  • Asheville Cardiology Associates
    Asheville, North Carolina 28803, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Pinehurst Medical Clinic
    Pinehurst, North Carolina 28374, United States
  • The Lindner Research Center The Christ Hospital Health Network
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • University of Toldedo Medical Center
    Toledo, Ohio 43614, United States
  • The Oregon Clinic
    Portland, Oregon 97225, United States
  • Lancaster General Hospital
    Lancaster, Pennsylvania 17601, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • AnMed Health Pulmonary and Sleep Medicine
    Anderson, South Carolina 29621, United States
  • VitaLink Research - Anderson
    Anderson, South Carolina 29621, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Stern Cardiovascular Foundation
    Germantown, Tennessee 38138, United States
  • Summit Medical Group
    Knoxville, Tennessee 37909, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-2650, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Houston Methodist Research Institute
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Texas Tech University Health Sciences Center
    Lubbock, Texas 79905, United States
  • Intermountain Medical Center
    Murray, Utah 84143, United States
  • Inova Heart and Vascular Institute
    Falls Church, Virginia 22042, United States
  • Sentara Cardiovascular Research Institute
    Norfolk, Virginia 23507, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Carilion Clinic
    Roanoke, Virginia 24014, United States
  • Providence Medical Research Center
    Spokane, Washington 99204, United States
  • West Virginia University Hospital
    Morgantown, West Virginia 26506, United States
  • Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Mar 2020, 25 months.

Results were first posted in Oct 2020, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2017
First posted
Feb 6, 2017
StartActual
Jan 30, 2018
Primary completionActual
Mar 2, 2020
CompletionActual
Mar 2, 2020
Results first posted
Oct 22, 2020
Last update
Oct 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03043651
Responsible party
Sponsor
First posted
Feb 6, 2017
Start date
Jan 30, 2018
Primary completion
Mar 2, 2020
Completion
Mar 2, 2020
Results posted
Oct 22, 2020
Last update
Oct 22, 2020

Study contacts

Mardi Gomberg-Maitland, MD
principal investigator · George Washington University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion